Table 2 Patients’ characteristics and clinical information
RA (n = 15) | OA (n = 5) | |
|---|---|---|
Age (years) | 62.9 ± 10.3 | 66.2 ± 9.7 |
Gender, n (% female) | 11 (73.3) | 5 (100.0) |
Disease duration (years) | 11.7 ± 9.0 | 5.7 ± 5.6 |
Stage (I/II/III/IV) | 1/1/11/2 | |
Class (I/II/III/IV) | 1/5/8/1 | |
DAS28-CRP | 3.5 ± 1.1 | |
CRP(mg/dL) | 2.4 ± 2.2 | |
MMP-3 (ng/mL) | 430.8 ± 531.5 | |
MTX use, n (%) | 9 (60.0) | |
MTX dose (mg/week) | 4.1 ± 3.6 | |
Oral steroid use, n (%) | 7 (46.7) | |
Oral steroid dose (mg/day) | 1.4 ± 1.7 | |
Biologics use, n (%) | 3 (20.0) | |
Sampling site | ||
Wrist joint, n | 3 | 0 |
Elbow joint, n | 1 | 0 |
Hip joint, n | 1 | 4 |
Knee joint, n | 10 | 1 |